Table 2.
Treatment characteristics, response to neoadjuvant chemotherapy, and histopathological tumor characteristic on surgical tissue.
| Characteristic | N (%) |
|---|---|
| Total | 142 |
| MRI | |
| No | 56 (39.4%) |
| Yes | 86 (60.6%) |
| Unknown | 0 |
| Time NACT-Surgery | Median 31.4 days (16–74) |
| <30 days | 63 |
| ≥30 days | 74 |
| Type surgery | |
| Conservative | 64 (46.4%) |
| Mastectomy | 74 (53.6%) |
| Unknown | 4 |
| SLNB | |
| No | 58 (41.1%) |
| Yes | 83 (58.9%) |
| Unknown | 1 |
| Type of NACT | |
| Anthracycline and taxane-based | 109 (76.8%) |
| Anthracycline or taxane-based | 6 (4.2%) |
| Platinum-based | 27 (19.0%) |
| Unknown | 0 |
| ypT | |
| 0 | 67 (47.9%) |
| 1 | 73 (52.1%) |
| Unknown | 2 |
| ypN | |
| 0 | 117 (82.9%) |
| 1 | 24 (17.1%) |
| Unknown | 1 |
| LN assessment | |
| ≤10 | 72 (51.4%) |
| >10 | 68 (48.6%) |
| Unknown | 2 |
| pCR | |
| No | 79 (56.1%) |
| Yes | 62 (43.9%) |
| Unknown | 1 |
| Residual cancer burden | |
| I | 3 (3.9%) |
| II | 59 (77.6%) |
| III | 14 (18.4%) |
| Unknown | 3 |
| TILs on residual tumor | |
| <30% | 39 (51.3%) |
| ≥30% | 37 (48.7%) |
| Unknown | 3 |
| Grading on residual tumor | |
| II | 4 (6.2%) |
| III | 61 (93.8%) |
| Unknown | 14 |
| Ki-67 on residual tumor | |
| <20 | 27 (37.5%) |
| ≥20 | 45 (62.5%) |
| Unknown | 7 |
| Ki67 pre- vs. post-NACT | |
| Stable/increased | 19 (27.1%) |
| Decreased | 51 (72.9%) |
| Unknown | 9 |
| LVSI on residual tumor | |
| No | 35 (72.9%) |
| Yes | 13 (27.1%) |
| Unknown | 31 |
| Adjuvant treatment | |
| No | 112 (79.4%) |
| Yes | 29 (20.6%) |
| Unknown | 1 |
| Time surgery-RT | Median, 84.6 days (43–171) |
| ≤90 days | 44 |
| >90 days | 21 |
MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; SLNB, sentinel lymph node biopsy; LN, lymph node; pCR, pathological complete response; LVSI, lymphovascular space invasion; RT, radiotherapy.